University Hospital of Bern-ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2023

  1. Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study

    The Lancet Haematology, Vol. 10, Núm. 11, pp. e902-e912